Hyperhomocysteinemia in Adult Patients: A Treatable Metabolic Condition

Nutrients. 2023 Dec 30;16(1):135. doi: 10.3390/nu16010135.

Abstract

Hyperhomocysteinemia (HHcy) is recognized as an independent risk factor for various significant medical conditions, yet controversy persists around its assessment and management. The diagnosis of disorders afffecting homocysteine (Hcy) metabolism faces delays due to insufficient awareness of its clinical presentation and unique biochemical characteristics. In cases of arterial or venous thrombotic vascular events, particularly with other comorbidities, it is crucial to consider moderate to severe HHcy. A nutritional approach to HHcy management involves implementing dietary strategies and targeted supplementation, emphasizing key nutrients like vitamin B6, B12, and folate that are crucial for Hcy conversion. Adequate intake of these vitamins, along with betaine supplementation, supports Hcy remethylation. Lifestyle modifications, such as smoking cessation and regular physical activity, complement the nutritional approach to enhance Hcy metabolism. For individuals with HHcy, maintaining a plasma Hcy concentration below 50 μmol/L consistently is vital to lowering the risk of vascular events. Collaboration with healthcare professionals and dietitians is essential for developing personalized dietary plans addressing the specific needs and underlying health conditions. This integrated approach aims to optimize metabolic processes and reduce the associated health risks.

Keywords: Marfanoid habitus; betaine; ectopia lentis; homocysteine; homocystinuria; hyperhomocysteinemia; inborn metabolic diseases; remethylation; thrombotic events; transsulfuration.

Publication types

  • Review

MeSH terms

  • Adult
  • Arteries
  • Behavior Therapy
  • Humans
  • Hyperhomocysteinemia* / complications
  • Hyperhomocysteinemia* / therapy
  • Metabolic Diseases*
  • Vitamins

Substances

  • Vitamins

Grants and funding

AECOM The Spanish Society for the Study of Inborn Errors of Metabolism collaborated in the publication and promotion of the article. Recordati Rare Diseases collaborates with AECOM to promote the identification of HCU patients and supports meetings and actions in education of professionals.